spravato_annual_worldwide_sales_2019_2026More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule has completed its migration into psychiatry, where it has become a blockbuster. Esketamine, the more potent S-enantiomer of that original compound, won FDA approval for treatment-resistant depression as a nasal spray in March 2019, then…
AbbVie files supplemental New Drug Application with FDA for cariprazine
AbbVie (NYSE: ABBV) has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) for major depressive disorder (MDD). FDA first approved cariprazine for schizophrenia and bipolar disorder in 2015. Current indications of the drug cover the acute treatment of manic or mixed episodes related to bipolar I disorder and depressive episodes associated with bipolar…